LUNG CANCER

Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non­–small cell lung cancer (NSCLC) whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.

Puneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

Although there are no drugs yet that target TP53 mutations in any tumor type, a recent analysis of a non&ndash;small cell lung cancer (NSCLC) sample set raises the prospect that a more detailed understanding of this aberration could eventually help direct therapy.

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, discusses how Myriad&#39;s myPlan addresses the risk of recurrence in lung cancer.

Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1&ndash;positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Almost 40% of patients with resected early-stage non&ndash;small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC) who progressed after first-line crizotinib.